HealthFDA approves groundbreaking new drug for pancreatic cancer

The Food and Drug Administration approved a groundbreaking oral drug for patients with the most aggressive form of pancreatic cancer. Daraxonrasib targets a KRAS gene mutation and doubled survival time among trial participants.